We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Guest Column: Woodcock Leaves a 40-Year Legacy of Extraordinary FDA Leadership
Guest Column: Woodcock Leaves a 40-Year Legacy of Extraordinary FDA Leadership
When the rare disease patient community was seeking to have the FDA pay more focused attention to orphan drugs, they asked Janet Woodcock for support. She established within CDER a new office dedicated to orphan drugs and rare diseases.